During the corresponding time, Keros Therapeutics Inc saw a revenue deteriorated by -98.76 % year on year, sequentially revenue grew by 601.82 %. While revenue at the Keros Therapeutics Inc 's corporate clients
Keros Therapeutics Inc's Comment on Sales, Marketing and Customers
The company serves customers who bill federal programs for products, including healthcare benefit programs and private third-party payors. Its operations involve HIPAA-covered entities such as certain healthcare providers, healthcare clearinghouses, health plans, and business associates handling individually identifiable health information. The U.S. federal Physician Payments Sunshine Act applies to manufacturers of drugs, devices, biologics, and medical supplies reimbursable under Medicare, Medicaid, or the Children’s Health Insurance Program. Under this act, payments and transfers of value are reported to physicians—including doctors, dentists, optometrists, podiatrists, and chiropractors—other healthcare professionals such as physician assistants and nurse practitioners, and teaching hospitals. The company also interacts with private insurers, which serve as non-governmental third-party payors. Additionally, state and foreign laws regulate pharmaceutical companies concerning compliance, reporting payments to healthcare providers, drug pricing, and the privacy and security of health information.
Keros Therapeutics, Inc. a biopharmaceutical firm dedicated to developing therapeutics targeting disorders arising from dysfunctional signaling of the transforming growth factor-beta (TGF-β) family of proteins, recently announced a voluntary halt in dosing for certain treatment arms of its Phase 2 TROPOS trial. This trial is assessing the safety and efficacy of cibotercept (KER-012) in conjunction with background therapy for patients with pulmonary arterial hypertension (PAH). Context of the TROPOS TrialThe TROPOS trial is a Phase 2 clinical study designed to evaluate cibotercept as a potential therapeutic option for patients suffering from PAH, a rare but severe condition characterized by high blood pressu...
In a significant advancement for the treatment of hematological disorders, Keros Therapeutics, Inc. a clinical-stage biopharmaceutical company, presented pivotal findings from its ongoing Phase 2 clinical trials of elritercept (KER-050) at the 66th American Society of Hematology Annual Meeting and Exposition (ASH) held from December 7-10, 2024, in San Diego, California. With a focus on patients suffering from myelodysplastic syndromes (MDS) and myelofibrosis (MF) conditions linked to dysfunctional signaling of the transforming growth factor-beta (TGF-β) protein family Keros Therapeutics is poised to redefine therapeutic strategies in the hematology space.Elritercept is a novel therapeutic approach that targ...
Advancing Treatments for Hematologic Disorders: Keros Therapeutics Pioneering Work on Elritercept (KER-050) Keros Therapeutics, Inc. (Nasdaq: KROS) has continuously made strides in developing innovative therapeutics targeting the dysfunctional signaling of transforming growth factor-beta (TGF-β) family proteins. This advancement is pivotal for treating a range of hematologic and metabolic disorders. This article delves into the recent findings and clinical developments Keros Therapeutics has presented regarding their flagship products, Elritercept (KER-050) and the novel ligand trap KER-065. Clinical Insights from the EHA and ASH Congress Elritercept (KER-050) in Myelodysplastic Syndromes (MDS) and Myelof...
Keros Therapeutics Inc’s Comment on Sales, Marketing and Customers
The company serves customers who bill federal programs for products, including healthcare benefit programs and private third-party payors. Its operations involve HIPAA-covered entities such as certain healthcare providers, healthcare clearinghouses, health plans, and business associates handling individually identifiable health information. The U.S. federal Physician Payments Sunshine Act applies to manufacturers of drugs, devices, biologics, and medical supplies reimbursable under Medicare, Medicaid, or the Children’s Health Insurance Program. Under this act, payments and transfers of value are reported to physicians—including doctors, dentists, optometrists, podiatrists, and chiropractors—other healthcare professionals such as physician assistants and nurse practitioners, and teaching hospitals. The company also interacts with private insurers, which serve as non-governmental third-party payors. Additionally, state and foreign laws regulate pharmaceutical companies concerning compliance, reporting payments to healthcare providers, drug pricing, and the privacy and security of health information.
Sources:
Keros Therapeutics Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: Keros Therapeutics Inc’s corporate clients.
For your research, we’ve provided 9 tables on Keros Therapeutics Inc corporate clients.
You can find them in the navigation menu under Customers & Markets.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
